Christopher J. McDonald
OverviewChristopher J. McDonald concentrates his practice on prosecuting complex securities fraud cases. Chris also works with the Firm’s Antitrust & Competition Litigation Practice, representing businesses, associations and individuals injured by anticompetitive activities and unfair business practices.
In the securities field, Chris is currently co-lead counsel in In re Schering-Plough Corporation / ENHANCE Securities Litigation, and lead counsel in In re Amgen Inc. Securities Litigation. He was also an integral part of the team that successfully litigated In re Bristol-Myers Squibb Securities Litigation, where Labaton Sucharow secured a $185 million settlement, as well as significant corporate governance reforms, on behalf of Bristol-Myers shareholders. The settlement with Bristol-Myers is the largest ever obtained against a pharmaceutical company in a securities fraud case that did not hinge on a restatement of financial results.
In the antitrust field, Chris was most recently co-lead counsel in In re TriCor Indirect Purchaser Antitrust Litigation, obtaining a $65.7 million settlement on behalf of the Class.
Chris began his legal career at Patterson, Belknap, Webb & Tyler LLP, where he gained extensive trial experience in areas ranging from employment contract disputes to false advertising claims. Later, as a senior attorney with a telecommunications company, Chris advocated before government regulatory agencies on a variety of complex legal, economic, and public policy issues. Since joining Labaton Sucharow, Chris’ practice has developed a focus on life sciences industries; his cases often involve pharmaceutical, biotechnology or medical device companies accused of wrongdoing.
During his time at Fordham University School of Law, Chris was a member of the Law Review. He is currently a member of the New York State Bar Association and the Association of the Bar of the City of New York.